← Back to Search

Histone Deacetylase Inhibitor

HBI-8000 + Pembrolizumab for Non-Small Cell Lung Cancer (HBI-8000 Trial)

Phase 2
Waitlist Available
Research Sponsored by HUYABIO International, LLC.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 38 months
Awards & highlights

Summary

This trial is testing a new cancer drug, HBI-8000, to see if it can help people with advanced lung cancer who have a protein called PD-L1.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~38 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 38 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective response rate (ORR)
Secondary outcome measures
Disease Control Rate (DCR)
Duration of response (DoR)
Progression-Free Survival (PFS)
+1 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Pneumothorax
5%
Malnutrition, Hypercalcemia and Weakness
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: HBI-8000 in combination with pembrolizumabExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

HUYABIO International, LLC.Lead Sponsor
11 Previous Clinical Trials
944 Total Patients Enrolled

Media Library

HBI-8000 (Tucidinostat) (Histone Deacetylase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05141357 — Phase 2
Non-Small Cell Lung Cancer Research Study Groups: HBI-8000 in combination with pembrolizumab
Non-Small Cell Lung Cancer Clinical Trial 2023: HBI-8000 (Tucidinostat) Highlights & Side Effects. Trial Name: NCT05141357 — Phase 2
HBI-8000 (Tucidinostat) (Histone Deacetylase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05141357 — Phase 2
~2 spots leftby Jul 2025